{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:49:47Z","timestamp":1790743787761,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012306","name":"Center for Innovative Medicine, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.berh.2023.101828","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T01:03:31Z","timestamp":1685063011000},"page":"101828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in remission induction therapy for ANCA-associated vasculitis"],"prefix":"10.1016","volume":"37","author":[{"given":"Adam","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-5542","authenticated-orcid":false,"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.berh.2023.101828_bib1","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jlb.50.6.539","article-title":"Antibodies against granule proteins activate neutrophils in vitro","volume":"50","author":"Charles","year":"1991","journal-title":"J Leukoc Biol"},{"issue":"7","key":"10.1016\/j.berh.2023.101828_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib4","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1182\/blood-2005-03-0921","article-title":"Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo","volume":"106","author":"Little","year":"2005","journal-title":"Blood"},{"issue":"6342","key":"10.1016\/j.berh.2023.101828_bib5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/bmj.285.6342.606","article-title":"Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?","volume":"285","author":"Davies","year":"1982","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.berh.2023.101828_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","article-title":"Cyclophosphamide therapy of severe systemic necrotizing vasculitis","volume":"301","author":"Fauci","year":"1979","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2023.101828_bib8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101828_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.berh.2023.101828_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/jpet.103.053256","article-title":"Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays","volume":"307","author":"Jin","year":"2003","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"5","key":"10.1016\/j.berh.2023.101828_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archinte.1979.03630420010007","article-title":"High-dose corticosteroids: their use in treating idiopathic rapidly progressive glomerulonephritis","volume":"139","author":"O\u2019neill","year":"1979","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener's granulomatosis","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2023.101828_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0002-9343(79)91081-7","article-title":"Intravenous pulse methylprednisolone therapy of acute primary crescenteric rapidly progressive glomerulonephritis","volume":"66","author":"Bolton","year":"1979","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2023.101828_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000167998","article-title":"Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis","volume":"9","author":"Bolton","year":"1989","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1016\/j.berh.2023.101828_bib15","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.berh.2023.101828_bib16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2023.101828_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101828_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials","volume":"54","author":"Robson","year":"2014","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/rheumatology\/kez001","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2023.101828_bib20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.berh.2023.101828_bib21","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in anca-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA, J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050507","article-title":"Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review","volume":"12","author":"Xiao","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.berh.2023.101828_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/qjmed\/90.6.401","article-title":"Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis","volume":"90","author":"Adu","year":"1997","journal-title":"QJM - Mon J Assoc Physicians"},{"issue":"10","key":"10.1016\/j.berh.2023.101828_bib26","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2023.101828_bib27","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2023.101828_bib28","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission","volume":"150","author":"Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2023.101828_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2023.101828_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.berh.2023.101828_bib33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2023.101828_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2023.101828_bib35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"4\u20135","key":"10.1016\/j.berh.2023.101828_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000431336","article-title":"Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab","volume":"41","author":"Shah","year":"2015","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J Nephrol"},{"issue":"11","key":"10.1016\/j.berh.2023.101828_bib38","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease","volume":"31","author":"Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.berh.2023.101828_bib39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","article-title":"B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study","volume":"34","author":"Martinez Del Pero","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"1","key":"10.1016\/j.berh.2023.101828_bib40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2023.101828_bib41","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"M\u00e9let","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101828_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.berh.2023.101828_bib43","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCAassociated vasculitis: a single-centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2023.101828_bib44","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2023.101828_bib45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","article-title":"Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review","volume":"18","author":"Wijetilleka","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.berh.2023.101828_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102986","article-title":"The COVID-19 pandemic and ANCA-associated vasculitis \u2013 reports from the EUVAS meeting and EUVAS education forum","volume":"20","author":"Kronbichler","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.berh.2023.101828_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"34","author":"Mcadoo","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.berh.2023.101828_bib48","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Galati","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Reports"},{"issue":"9","key":"10.1016\/j.berh.2023.101828_bib50","first-page":"4135","article-title":"Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial [Abstract]","volume":"73","author":"Terrier","year":"2021","journal-title":"Arthritis Rheumatol [Internet]"},{"issue":"4","key":"10.1016\/j.berh.2023.101828_bib51","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","article-title":"Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.berh.2023.101828_bib53","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"1\u20137","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2023.101828_bib54","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2023.101828_bib55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2023.101828_bib56","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.berh.2023.101828_bib57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Supplementary appendix: avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"10.1016\/j.berh.2023.101828_bib58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/rheumatology\/kez063.050","article-title":"Randomized phase 3 trial evaluating the safety and efficacy of avacopan in patients with new or relapsing anca-associated vasculitis","volume":"58","author":"Merkel","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101828_bib59","series-title":"Renal recovery for patients with baseline eGFR \u2264 20 in the avacopan ADVOCATE trial","author":"Cortazar","year":"2022"},{"issue":"12","key":"10.1016\/j.berh.2023.101828_bib60","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/rheumatology\/kez190","article-title":"Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab","volume":"58","author":"Ribes","year":"2019","journal-title":"Rheumatology"},{"issue":"20","key":"10.1016\/j.berh.2023.101828_bib61","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib62","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.berh.2023.101828_bib63","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/rheumatology\/kez311","article-title":"The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"59","author":"Shimizu","year":"2020","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2023.101828_bib64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.berh.2023.101828_bib66","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","article-title":"Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis","volume":"57","author":"Walsh","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101828_bib67","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.berh.2023.101828_bib68","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1681\/ASN.2005080870","article-title":"Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement","volume":"17","author":"De Lind Van Wijngaarden","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.berh.2023.101828_bib69","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101828_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.berh.2023.101828_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064597","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline","author":"Zeng","year":"2022","journal-title":"BMJ"},{"issue":"153","key":"10.1016\/j.berh.2023.101828_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0022-2019","article-title":"Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis","volume":"28","author":"Collins","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"18","key":"10.1016\/j.berh.2023.101828_bib73","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2023.101828_bib74","article-title":"Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?","author":"Cassone","year":"2020","journal-title":"Respir Med Case Reports"},{"issue":"2","key":"10.1016\/j.berh.2023.101828_bib75","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1681\/ASN.2019060618","article-title":"Therapeutic myeloperoxidase inhibition attenuates neutrophil activation, anca-mediated endothelial damage, and crescentic GN","volume":"31","author":"Antonelou","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.berh.2023.101828_bib76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013101061","article-title":"CXCL5 drives neutrophil recruitment in TH17-mediated GN","volume":"26","author":"Disteldorf","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.berh.2023.101828_bib77","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000506532","article-title":"Treatment outcomes of anti-neutrophil cytoplasmic autoantibody-associated vasculitis in patients over age 75 Years: a meta-analysis","volume":"51","author":"Morris","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.berh.2023.101828_bib78","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.04760422","article-title":"Rituximab in the frail and elderly with severe ANCA-associated GN","volume":"17","author":"Brix","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.berh.2023.101828_bib79","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000494223","article-title":"Diagnostic accuracy of frailty screening methods in advanced chronic kidney disease","volume":"141","author":"Nixon","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.berh.2023.101828_bib80","series-title":"Original article Long-term outcomes in elderly patients with","author":"Mcgovern","year":"2019"},{"issue":"3","key":"10.1016\/j.berh.2023.101828_bib81","first-page":"1","article-title":"Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties","volume":"6","author":"Wang","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.berh.2023.101828_bib82","first-page":"1","article-title":"The limitations of frailty assessment tools in ANCA-associated vasculitis","author":"Floyd","year":"2023","journal-title":"J Frailty Aging"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:25:12Z","timestamp":1761499512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521694223000141"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101828","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in remission induction therapy for ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101828"}}